Recent Progress on Masitinib for Multiple Sclerosis
AB Science SA has recently shared some exciting news about masitinib, a treatment currently being evaluated for progressive forms of multiple sclerosis (MS). This update came after key insights were revealed at the latest European Committee for Treatment and Research in Multiple Sclerosis conference. Masitinib, a significant compound developed by AB Science (PARIS:AB), is being studied for its potential to effectively manage this complex neurological condition.
Insights from the MAXIMS Study
The exploration of masitinib is rooted in the MAXIMS study (AB20009). This comprehensive, randomized, double-blind, phase 3 study examines the impact of masitinib given at a dosage of 4.5 mg/kg/day on patients diagnosed with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive multiple sclerosis (nSPMS). Eligible participants must meet specific criteria, including having an Expanded Disability Status Scale (EDSS) score between 3.0 and 6.0, showing signs of disease progression within the preceding two years, and exhibiting no T1 Gadolinium-enhancing brain lesions.
Scientific Insights on Microglia Targeting
During the ECTRIMS 2024 conference, important discoveries were presented, particularly regarding tolebrutinib, a medication also aimed at microglia in nSPMS. This research supports the idea that targeting microglia could lead to significant progress in treating MS. While tolebrutinib specifically uses Bruton Tyrosine Kinase (BTK) to target microglia, masitinib takes a different route by focusing on the Macrophage Colony Stimulating Factor Receptor-1 (M-CSFR1). This innovative method yielded positive outcomes in a phase 2B study (AB07002), aligning well with what was observed with tolebrutinib.
Promising Study Results on Efficacy
The findings from the AB07002 study reveal encouraging results. For example, at the three-month check-in, EDSS progression with masitinib was reduced by 37%, compared to a 23% reduction noted with tolebrutinib in the Hercules study. Furthermore, confirmed EDSS progression was decreased by 32% with masitinib at the six-month mark, while tolebrutinib showed a decrease of 31%, indicating a strong efficacy for masitinib.
Improvements Noted in Functionality
Beyond the reduction in disability progression, masitinib also showed a significant boost in manual dexterity as indicated by the 9-hole peg test, achieving a promising p-value of 0.0388. Additionally, studies have demonstrated that masitinib can lower serum neurofilament light chain (NfL) levels in animal models of MS, suggesting a potential decrease in neuronal damage.
Profile and Long-Term Safety
Masitinib has established a solid safety record, having been used extensively for various non-oncological conditions. Up to now, around 2,200 patients have received at least one dose of masitinib, with over 1,300 having been treated for more than six months and nearly 1,000 for over a year. This extensive usage contributes valuable insight into its long-term safety and tolerability.
Conclusion and Future Outlook
In conclusion, masitinib stands out as a viable alternative to BTK inhibitors in the treatment of both primary and non-active secondary progressive MS. Professor Patrick Vermersch, MD, a key figure in the MAXIMS study, highlighted the significance of the data shared about tolebrutinib, emphasizing the potential for new therapeutic pathways to meet the unmet medical needs of MS patients.
AB Science remains committed to advancing the scientific reasoning behind developing masitinib and substantiating the promising outcomes from the AB07002 study. By concentrating on conditions with significant unmet medical needs, the company showcases its dedication to improving patient outcomes.
Frequently Asked Questions
What is masitinib?
Masitinib is a protein kinase inhibitor that AB Science is investigating for its potential to treat progressive forms of multiple sclerosis.
What is the MAXIMS study?
The MAXIMS study is a phase 3 clinical trial evaluating the effectiveness of masitinib in patients with progressive types of MS.
How does masitinib compare to tolebrutinib?
Both masitinib and tolebrutinib target microglia, but they do so through different pathways, with masitinib focusing on the M-CSFR1 receptor.
What safety data is available for masitinib?
Masitinib boasts a substantial safety record, having been administered to over 2,200 patients, demonstrating long-term safety across multiple indications.
What are the next steps for AB Science?
AB Science intends to continue its research on masitinib, with the goal of validating its efficacy in treating MS and addressing the unmet medical needs in this area.
